UroGen Pharma Ltd. (URGN) Operating margin 2016–2025
UroGen Pharma Ltd. (URGN) operating margin by fiscal year — reported operating income divided by reported revenue.
-113.7%FY2025 · since FY2016: 4.6% → -113.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -113.7% | -6.7 pp |
| FY2024 | -107.1% | -27.8 pp |
| FY2023 | -79.2% | +43.6 pp |
| FY2022 | -122.8% | +69.3 pp |
| FY2021 | -192.1% | +882.0 pp |
| FY2020 | -1074.2% | +607137.0 pp |
| FY2019 | -608211.1% | -601368.9 pp |
| FY2018 | -6842.2% | -6597.7 pp |
| FY2017 | -244.5% | -249.1 pp |
| FY2016 | 4.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →